Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001.

Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Abstract Text:

Michel R Joffres,Tripthi V Kamath,G Rhys Williams,Jill Casey,Lawrence W Svenson,

BACKGROUND: Guidelines for the treatment of hyperlipidemia aim at improving the management of people at a higher risk of developing cardiovascular disease. OBJECTIVES: To study the potential impact of hyperlipidemia guidelines on health care use in two Canadian provinces with different levels of hyperlipidemia. METHODS: Trends in physician billing were obtained from Alberta between 1990 and 2000 and from Nova Scotia between 1994 to 2001 using the 272 primary diagnostic code for hyperlipidemia. Record linkage between a 272 code and a prescription in the subsequent six months was made through the Pharmacare database (which automatically registers all individuals 65 years of age and over). Data were also linked between the 1995 Nova Scotia Health Survey and the Pharmacare data. RESULTS: Trends in hyperlipidemia codes were similar in Alberta and Nova Scotia by sex and age, with acceleration in the final years of the study. Approximately 5% of the adult population had a diagnosis of hyperlipidemia. Less than 60% of people aged 65 years and over with a 272 code filled an antilipemic prescription in the subsequent six months. Using the National Cholesterol Education Program Adult Treatment Panel III classification and the 1995 Nova Scotia Health Survey, less than 10% of the participants aged 65 years and over had a corresponding diagnostic code of 272, while more than half could be classified as having hyperlipidemia. In 1995, approximately one-half of people at high risk, with a 272 code in the subsequent five years, had a prescription for antilipemic drugs. CONCLUSIONS: Despite some limitations, these data show a discrepancy between guideline development and practice, leaving a high number of at-risk individuals undiagnosed and untreated. Mechanisms need to be put in place to ensure better classification and follow-up of people with hyperlipidemia at risk for cardiovascular disease.

Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Publishing Authors By Initials

MR Joffres,TV Kamath,GR Williams,J Casey,LW Svenson,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: The Canadian journal of cardiology

VOLUME: 20

Page Numbers: 767-72

Journal Abbreviation:

ISSN: 1916-7075

DAY: 3

MONTH: Jun

YEAR: 2004

Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8510280

Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: statistics & numerical data

Chemical & Substance for Abstract: Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Information

Substance Name: Lipoproteins

Registry Number: 0

Grant and Affiliation Information for Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001.

AFFILIATION: Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia. michel.joffres@dal.ca

Country: Canada

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Can J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001 Related Publications

• A standardized human T-lymphocyte proliferation assay for detecting soluble accessory factors from monocytes. II. Interleukin-1 production and detection.
• Breast self-examination behaviours among female university students.
• CRITICISM OF THE LABORATORY ACCREDITATION PROGRAM.
• Decisions among time saving options: When intuition is strong and wrong.
• Evidence of gender bias in legal insanity evaluations: A case vignette study of clinicians, judges and students.
• Health disparities in chickenpox or shingles in Alberta?
• Heterologous expression of the alcohol dehydrogenase (adhI) gene from Geobacillus thermoglucosidasius strain M10EXG.
• Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001.
• Mental health services in Edmonton: an assessment of service availability.
• Should a new tuberculosis vaccine be administered intranasally?
• Trauma systems and timing of patient transfer: are we improving?
• [Toll-like receptors. What can we learn about the immune system from banana flies and a mouse strain]